International Urology and Nephrology

, Volume 50, Issue 7, pp 1293–1300 | Cite as

The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease

  • Melahat Coban
  • Ayca Inci
Nephrology - Original Paper



Autosomal dominant polycystic kidney disease (ADPKD) is a common congenital chronic kidney disease (CKD). We report here the relationship of serum angiopoietin-1 (Ang-1), Ang-2, and vascular endothelial growth factor (VEGF) with total kidney volume (TKV), total cyst volume (TCV), and renal failure in adult ADPKD patients at various stages of CKD.


This cross-sectional study was conducted with 50 patients diagnosed with ADPKD and a control group of 45 age-matched healthy volunteers. In patient group, TKV and TCV were determined with upper abdominal magnetic resonance imaging, whereas in controls, TKV was determined with ultrasonography according to ellipsoid formula. Renal function was assessed with serum creatinine, estimated glomerular filtration rate (eGFR), and spot urinary protein/creatinine ratio (UPCR). Ang-1, Ang-2, and VEGF were measured using enzyme-linked immunosorbent assay.


Patients with ADPKD had significantly higher TKV (p < 0.001) and UPCR (p < 0.001), and lower eGFR (p ≤ 0.001) compared to the controls. Log10Ang-2 was found to be higher in ADPKD patients at all CKD stages. Multiple linear regression analysis showed that there was no association between log10Ang-1, log10Ang-2, or log10VEGF and creatinine, eGFR, UPCR, log10TKV (p > 0.05).


There was no association of serum angiogenic growth factors with TKV or renal failure in ADPKD patients. Increased serum Ang-2 observed in stages 1–2 CKD suggests that angiogenesis plays a role in the progression of early stage ADPKD, but not at later stages of the disease. This may be explained by possible cessation of angiogenesis in advanced stages of CKD due to the increased number of sclerotic glomeruli.


Autosomal dominant polycystic kidney disease Angiopoietin Vascular endothelial growth factor Total kidney volume Renal failure 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Gabow PA, Johnson AM, Kaehny WD et al (1992) Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41:1311–1319CrossRefPubMedGoogle Scholar
  2. 2.
    Somlo S, Chapman AB (2012) Autosomal dominant polycystic kidney disease. In: Coffman TM, Falk RJ, Molitoris BA, Neilson EG, Schrier RW (eds) Schrier’s diseases of the kidney, 9th edn. Lippincott Williams & Wilkins, Philadelphia, pp 519–563Google Scholar
  3. 3.
    Grantham JJ, Torres VE, Chapman AB et al (2006) CRISP investigators: volume progression in polycystic kidney disease. N Engl J Med 354:2122–2130CrossRefPubMedGoogle Scholar
  4. 4.
    Chapman AB, Guay-Woodford LM, Grantham JJ et al (2003) Consortium for radiologic imaging studies of polycystic kidney disease cohort. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 64:1035–1045CrossRefPubMedGoogle Scholar
  5. 5.
    Levine E, Cook LT, Grantham JJ (1985) Liver cysts in autosomal-dominant polycystic kidney disease: clinical and computed tomographic study. Am J Roentgenol 145:229–233CrossRefGoogle Scholar
  6. 6.
    O’Neill WC, Robbin ML, Bae KT et al (2005) Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the consortium of renal imaging studies in polycystic kidney disease (CRISP). Am J Kidney Dis 46:1058–1064CrossRefPubMedGoogle Scholar
  7. 7.
    Diab KM, Ollmar S, Sevastik JA, Willers U, Svensson A (1998) Volumetric determination of normal and scoliotic vertebral bodies. Eur Spine J 7:282–288CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Harris PC, Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60:321–337CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Grantham JJ, Chapman AB, Torres VE (2006) Volume progression in autosomal dominant polycystic kidney disease: the majör factor determining clinical outcomes. Clin J Am Soc Nephrol 1:148–157CrossRefPubMedGoogle Scholar
  10. 10.
    Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998CrossRefPubMedGoogle Scholar
  11. 11.
    Nichols MT, Gidey E, Matzakos T et al (2004) Secretion of cytokines and growth factors into ADPKD liver cyst fluid. Hepatology 40:836–846CrossRefPubMedGoogle Scholar
  12. 12.
    Bello-Reuss E, Holubec K, Rajaraman S (2001) Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 60:37–45CrossRefPubMedGoogle Scholar
  13. 13.
    Wei W, Popov V, Walocha JA, Wen J, Bello-Reuss E (2006) Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int 70:1261–1268CrossRefPubMedGoogle Scholar
  14. 14.
    Levey AS, Stevens LA, Schmid CH et al (2009) CKD-EPI (chronic kidney disease epidemiology collaboration): a new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Alam A, Dahl NK, Lipschutz JH et al (2015) Total kidney volume in autosomal dominant polycystic kidney disease: a biomarker of disease progression and therapeutic efficacy. Am J Kidney Dis 66:564–576CrossRefPubMedGoogle Scholar
  16. 16.
    Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2009) Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4:820–829CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Bakker J, Olree M, Kaatee R et al (1999) Renal volume measurements: accuracy and repeatability of US compared with that of MR imaging. Radiology 211:623–628CrossRefPubMedGoogle Scholar
  18. 18.
    Gall EC, Audrézet M, Chen J et al (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24:1006–1013CrossRefGoogle Scholar
  19. 19.
    Grantham JJ, Cook LT, Torres VE et al (2008) Determinants of renal volume in autoso-mal dominant polycystic kidney disease. Kidney Int 73:108–116CrossRefPubMedGoogle Scholar
  20. 20.
    Gale NW, Yancopoulos GD (1999) Growth factors acting via endothelial cell specific receptor tyrosine kinases: VEGFs, angiopoietins, and ehrins in vascular development. Genes Dev 13:1055–1066CrossRefPubMedGoogle Scholar
  21. 21.
    Minchenko A, Bauer T, Salceda S, Caro L (1994) Hypoxic stimulation of vascular endothelial growth factor expression in vivo and in vitro. Lab Invest 71:374–379PubMedGoogle Scholar
  22. 22.
    Shima DT, Adamis AP, Ferrara N et al (1995) Hypoxic induction of endothelial cell growth factors in retinal cells. Mol Med 1:182–193PubMedPubMedCentralGoogle Scholar
  23. 23.
    Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50:203–218CrossRefPubMedGoogle Scholar
  24. 24.
    Tao Y, Kim J, Yin Y et al (2007) VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int 72:1358–1366CrossRefPubMedGoogle Scholar
  25. 25.
    Kang D-H, Johnson RJ (2003) Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 12:43–49CrossRefPubMedGoogle Scholar
  26. 26.
    Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB (2007) VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice. Am J Physiol Cell Physiol 293:C419–C428CrossRefPubMedGoogle Scholar
  27. 27.
    Raina S, Honer M, Krämer SD et al (2011) Anti-VEGF antibody treatment accelerates polycystic kidney disease. Am J Physiol Renal Physiol 301:F773–F783CrossRefPubMedGoogle Scholar
  28. 28.
    Ostendorf T, Kunter U, Loos A, Eitner F, Regele H, Kerjaschki D et al (1999) VEGF165 mediates glomerular endothelial repair. J Clin Invest 104:913–923CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    David S, Kümpers P, Lukasz A et al (2010) Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant 25:2571–2576CrossRefPubMedGoogle Scholar
  30. 30.
    Reed BY, Masoumi A, Elhassan E et al (2011) Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int 79:128–134CrossRefPubMedGoogle Scholar
  31. 31.
    Lim HS, Lip GYH, Blann AD (2005) Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 180:113–118CrossRefPubMedGoogle Scholar
  32. 32.
    Mayer G (2011) Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transplant 26:1132–1137CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Yang YB, Liu F, Huang SM (2007) The expression and significance of the angiopoietin-1 in the kidney of diabetic rats. Sichuan Da Xue Xue Bao Yi Xue Ban 38:93–96PubMedGoogle Scholar
  34. 34.
    Chang FC, Lai TS, Chiang CK et al (2013) Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease. PLoS ONE 8:e54668CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Brenchley P (1996) VEGF/VPF: a modulator of microvascular function with potential roles in glomerular pathophysiology. J Nephrol 9:10–17Google Scholar
  36. 36.
    Webb NJA, Watson CJ, Roberts ISD et al (1999) Circulating VEGF is not increased during relapses of steroid-sensitive nephrotic syndrome. Kidney Int 55:1063–1071CrossRefPubMedGoogle Scholar
  37. 37.
    Jones DB (1974) Arterial and glomerular lesions associated with severe hypertension. Light and electron microscobic studies. Lab Invest 31:303–313PubMedGoogle Scholar
  38. 38.
    Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E (1992) Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 42:1259–1265CrossRefPubMedGoogle Scholar
  39. 39.
    Shulman K, Rosen S, Tognazzi K, Manseau E, Brown A (1996) Expression of vascular permeability factor is altered in many glomerular diseases. J Am Soc Nephrol 7:661–666PubMedGoogle Scholar
  40. 40.
    Huang JL, Woolf AS, Long DA (2013) Angiogenesis and autosomal dominant polycystic kidney disease. Pediatr Nephrol 28:1749–1755CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of NephrologyAntalya Training and Research HospitalAntalyaTurkey

Personalised recommendations